We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+6.36%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$410M
AUM Growth
+$106M
Cap. Flow
+$109M
Cap. Flow %
26.67%
Top 10 Hldgs %
62.72%
Holding
47
New
9
Increased
19
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$42M
2
FOLD
Amicus Therapeutics
FOLD
+$13.6M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$12.3M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.21M
5
BHVN icon
Biohaven
BHVN
+$7.83M

Top Sells

Rank Stock Value
1
SDGR icon
Schrodinger
SDGR
+$7.6M
2
ISRG icon
Intuitive Surgical
ISRG
+$6.93M
3
MIRM icon
Mirum Pharmaceuticals
MIRM
+$6.38M
4
ABCL icon
AbCellera Biologics
ABCL
+$6.28M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.99M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$49.6M 12.11%
1,773,649
+458,751
+35% +$12.3M
UNH icon
2
UnitedHealth
UNH
$353B
$34.3M 8.37%
+110,000
New +$42M
MGTX icon
3
MeiraGTx Holdings
MGTX
$1.33B
$29.9M 7.29%
4,587,423
+895,877
+24% +$5.29M
ADCT icon
4
ADC Therapeutics
ADCT
$146M
$28.1M 6.84%
10,467,771
+924,767
+10% +$1.95M
BBIO icon
5
BridgeBio Pharma
BBIO
$15B
$20.4M 4.98%
472,687
-137,313
-23% -$4.99M
ROIV icon
6
Roivant Sciences
ROIV
$25.1B
$20.4M 4.97%
1,808,539
-17,624
-1% -$191K
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
$19.9M 4.86%
3,480,044
+2,100,661
+152% +$13.6M
JANX icon
8
Janux Therapeutics
JANX
$1.1B
$19.7M 4.81%
853,904
+164,003
+24% +$4.32M
KURA icon
9
Kura Oncology
KURA
$1.13B
$18.4M 4.48%
3,181,184
+1,102,869
+53% +$6.76M
ZYME icon
10
Zymeworks
ZYME
$2.02B
$16.4M 4.01%
1,309,904
+352,675
+37% +$4.2M
ICLR icon
11
Icon
ICLR
$13.1B
$14.3M 3.5%
98,558
+38,459
+64% +$5.45M
ARGX icon
12
argenx
ARGX
$64B
$12.1M 2.96%
22,000
+8,300
+61% +$4.82M
MIRM icon
13
Mirum Pharmaceuticals
MIRM
$5.94B
$10.2M 2.48%
200,000
-143,326
-42% -$6.38M
SNDX icon
14
Syndax Pharmaceuticals
SNDX
$1.74B
$10.1M 2.47%
1,079,673
+470,421
+77% +$5.18M
TECX
15
Tectonic Therapeutic
TECX
$696M
$8.78M 2.14%
442,056
+43,171
+11% +$875K
CRNX icon
16
Crinetics Pharmaceuticals
CRNX
$9B
$8.57M 2.09%
+298,123
New +$9.21M
CTMX icon
17
CytomX Therapeutics
CTMX
$699M
$7.98M 1.95%
3,517,113
-412,895
-11% -$666K
IMVT icon
18
Immunovant
IMVT
$8.51B
$7.67M 1.87%
479,400
+119,400
+33% +$1.81M
BHVN icon
19
Biohaven
BHVN
$2.33B
$7.61M 1.85%
539,071
+439,071
+439% +$7.83M
CON
20
Concentra Group Holdings
CON
$4.37B
$6.42M 1.57%
+312,105
New +$6.67M
LIVN icon
21
LivaNova
LIVN
$4.43B
$6.3M 1.54%
140,000
+12,700
+10% +$524K
DXCM icon
22
DexCom
DXCM
$34.3B
$6.11M 1.49%
+70,000
New +$5.49M
CDNA icon
23
CareDx
CDNA
$2.58B
$5.92M 1.44%
302,808
+166,215
+122% +$2.95M
SEM
24
DELISTED
Select Medical
SEM
$5.37M 1.31%
+353,820
New +$5.52M
STTK icon
25
Shattuck Labs
STTK
$707M
$5.26M 1.28%
6,638,935
– –
1
2

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q2 2025 Portfolio in Review

As of Q2 2025, Prosight Management held 47 positions worth $410M, up 35% from $304M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Prosight Management deployed $109M of net new capital in Q2 2025, opening 9 new positions and adding to 19 existing holdings. Its largest new stake was UnitedHealth: 110,000 shares worth $34.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Mirum Pharmaceuticals, an estimated $6.38M trimmed.

  • Prosight Management's largest Q2 2025 buy was UnitedHealth: 110,000 shares worth $34.3M.
  • Prosight Management added most to Amicus Therapeutics in Q2 2025, an estimated $13.6M increase.
  • Prosight Management's biggest Q2 2025 reduction was Mirum Pharmaceuticals, cutting an estimated $6.38M.
  • Prosight Management fully exited Schrodinger in Q2 2025, selling an estimated $7.6M.
  • Prosight Management's ten largest holdings make up 63% of its $410M portfolio in Q2 2025.
  • Prosight Management opened 9 new positions and closed 8 in Q2 2025.
  • Prosight Management's portfolio value rose 35% quarter-over-quarter to $410M.

Based on Prosight Management's 13F filing for Q2 2025, filed 14 Aug 2025.